Daniel Cagney Selected Research

Daniel Cagney Research Topics

7	Neoplasms (Cancer) 01/2024 - 01/2020
4	Glioblastoma (Glioblastoma Multiforme) 01/2024 - 04/2020
3	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 07/2023 - 01/2017
2	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2021
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2017
2	COVID-19 01/2021 - 04/2020
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2017
1	Kidney Neoplasms (Kidney Cancer) 07/2023
1	Adenocarcinoma of Lung 01/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Death (Near-Death Experience) 09/2019
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 04/2010

2	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2017
1	Bevacizumab (Avastin)FDA Link 01/2024
1	Temozolomide (Temodar)FDA LinkGeneric 01/2024
1	Biomarkers (Surrogate Marker)IBA 09/2023
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2023
1	MethyltransferasesIBA 09/2023
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	AGuIXIBA 01/2021
1	GadoliniumIBA 01/2021
1	Radiation-Sensitizing AgentsIBA 01/2021
1	Estrogen ReceptorsIBA 01/2020
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2020
1	human ERBB2 proteinIBA 01/2020
1	Hormones (Hormone)IBA 01/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	L 644711 (B-3(+))IBA 04/2010